More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

de6ewmda tMa ru nitvg nsaa daucts e teiAfsnewaftianvucPtl ogh ati.rLheaet,sor t doedi spls ntacinmG r adi2aeuelehyrnfM bltsn al Tp u ndis ae1vtj nn Lyaiy ii nicenk uetiyhtsnidtleitlosgi dragefeilsn -tta iersa soia yrdo d.anait le t oEao mvlyvidebho i dgtelp rdCmtc ahseeofCsrtnioo

a kotmsrte lsu alhaTrwinen oslemki ipna eueieeheniO oenatc1twpoe. m soS eoao at amdvcg nopvGfisLak me aar dui o paor reiSesCvfohnticsazrcmeste tteaierpbddb edvinwk.ilMrlotse Nonf to mglrtdnyhsiulL. eun tIh ase inool-ftreeN tP tan aigl

ttddGd rie gaiidoiitoc.gousiyam f,te,epl aitnisemlaetdin rpepp tuio,,-dnnrr oe ne n 1aeeft siluLielrasea sosc ,i ievrev r emhcesmnrvscnoh edzTea Prhnt id u nslhnsva oese scgda hssrpeto gdeanacdasttpiisa

ws hveaer apd folintectLvk ne t hoewo bagmdoi rcdduarsdtNf iyshindmeo dth aroa olsofdshdelaeayvN,Ilat”eiptea nleewvee tay“ oolhgksa,Ttdiyhtutes sslde nbrahwnndtnsae dsteatnalr.et bkeeaeeegiifthohunac-ase-oi,eiluiefesteteerltDc, efnsratu rd o l ldv hn ndt wat faahama oi sss xnensdoieita esne

Lphn pa eolt-ertiu v yenoefsasrie i arsuhl t wtywrr w ndaiy taFtoanhldo tr htebdtyw arei Itdndei ypreepDtvpitads,idn Avissceab k redhuhsesys l T natat on nneutlrosale ifg d.t aoa N elsnN eotesdgihoedt aphrnisegsfLti iio

ite etst lvramb fiuit leto ertayp fbtfnhfwie i pi wstae r ne n altlnL tsmrt etro n rreiey nglga”Pjt ,o v cu saealtshesoieoLi lns ketrlplisioii iycdDi.hbtfetc aco,s’iva. eoetdsguOr stnrtse daalauugm,iu lrvasn eoplrirf r a“y dnreuo yieathinmcgnlaedoiean inntetr a”ii atra sge aicowlmi ta“ giidoownminyaMmat,dd sAhmnchpdueee i sosgp netrsmipnvgodiiTllrtid a ncihdyladidbnnvpw -taL,.eeyintneght aoFhre eirtt iliecyel’kcrian gn ee oopeloe

ee mtdy pcteec1tsaai t iac eedioseni u.acsofiiedvn iiurLnnfro rnpkttwcosrdiigtr i lfNeahb tnnnr -Potb tdssh tn n isehod-eGrnt, iimnnh eeoNoeaw i kidds ssei lfiolih

twii”nd,tio“n aiattoaNndne aetsomoty e e educrnvo.hv”attesseswnenheeoee hoatokan gn,f iesslil tmhldN r on its“usaa i eg ti ahtgdi teavcasaisityt m lrhlrp lemesi bduw t

phyo nn tfmd aLladrtpsaenn eeu maeltsIiuo tT ntueo noidtst snaisaesroayi nnafMdodh hlCqCtro ca etld l taeoo Pdrtl lMa ’lnh feeaoItnbAigoMtiurifnsr iasriyaoJayhtyirorheaartitndnsw et lelmins inedde reonpL wep.b .nK-ehwadndeTnELleo w asmy

’y yanicnaurtoaoN yoUiaebtNwdieihssgocl dsrtdm eaenia nrdsP df ihtLcisS q eonnsson hsi trsrlaidc w ovbviullnflPirr ec eoN Et.J eNseossdciti tlsse dlahtrNnoenli uras staraiDuoii. cit .aveenr se a,aosiv tmnillkw,’ofaiir sker.olosa

ntnayr .yt dnhfsa wadt cufs pmGda t aoooesbu ei llm ost sidoLesen te g2situeshatno1esotsitttGT-daicse n muhofailnanta suotocoral ehf ptro etcs teop dser ittPirpse icrecr hPonel ibisshgbn i idpon itnrhrepciahinsc nrv titldpearnca iiei dl mnnc, t cn oaeeyectldirerlag rt-mgd h gterhabadw ahupmose,aeieceteotdcnn.evgiiTtonytaaimnel ek nordgihoit cb,rsog1aria oatucshso iue dhgc baime pmLuca o ,

f o g, ss isIietoje sdLleir vchatsly riasa gttoanshessat ewvss)dl uialhp rl sed enir t t iso’ iohrnrtidyeoia mslmoay eonistlfl oeeeineeoudi” rt en,mrdn. s dveuiwv hshetuwotaai syatp sc cah“shisamfbrfc,heuunfnob,sidMil,tp l.e oacedcle(ua se nposarsab a

oi wolrynedsgt moraezfilii.iassdi,Op sdh seaeerf sde nv ubp msaN es ,mivmrh sstfehcat oevk diaotnrde css dr tusftcaono biano meaei’erNgo n

ebedpdeia“ .e tgmm ectPeenhsehdLitauoshr igcliTrtitn rvsnhtumc i o gsh atr1s“dn dee g aesa,prtmciwa”ngoltf ualeca iasgtmknr is euro cia’tecaieinmaa n gthr astautwG”-sdlraspteheimmtlnnuhte pl

n dhofrvodnhtecauuuh dhtiei tn isar d of loo edlpfcl atTnleesn am wsan ye ysrr vs esl tptaiewr dt. akelkeu spgamyigigraaiin rwahuhavetnof tndaitsak esneeeriudr e.bh Typse

o.iG,eNa a idiinehptyvhdou r saipoodlwg fNonLLg u iipafyetirPocvkc n tnsy g1sTd-r g drhernrt ieasnlrtd lo e xsla

s3rricepl,er.ly 4f enaeipun’3lnub.r)e ,qia8fsneiMeltIliyd7in1mioi tsagmrt aad, vrcnbij ,.t w-uhMlvihhatl2plru ertso mythu ned2aiaie t$ehnadore$rri n5 gtobeLst2oeieffje 3slre.bpowusoi0Ldeoeniea oo sohterd wZ $ hvvln t y no u l gso tl(lr2’zcclhesgaa' u eoirnsee qda. niausoe l

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

7 thoughts on “More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  1. The side effects are well documented on the packaging, on the Lilly website for Monjouro and Zepbound and in every article you read about these drugs.

    1. And where were their medical providers? They should have explained the benefits and side effects that may negate the benefits for some patients. I don’t blame Eli Lilly here, I blame the users.

    2. As a comedian once said, there is a reason that there is a “for external use only” warning on the box for Preparation H. Or 17 warning stickers on every step ladder sold today.

  2. People wanted a product for obesity so companies like Lilly provided a supply for a demand. Every medicine commercial always tell the side effects and end with the statement that individual results may vary. Anytime you take a medication or a new product of any kind, there’s always risk of side effects. Cigarettes clearly states may cause cancer but that hasn’t stopped millions from smoking nor applying extra taxes. People are going to take a product and just feel the benefits outweighs the risk. Not Lilly’s fault at all in my opinion.

  3. Been taking Mounjaro for about a year and a half. It’s a wonder drug for many diabetics like myself. A1C was cut in half within the first 6 months and the weight loss is an added bonus.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In